Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Andy Page, David Lane, Mollie Roth

Premium

Direct-to-consumer genomics testing firm 23andMe has appointed Andy Page as its president, a newly created post. Page, who has served as a member of 23andMe's board of directors for the past year, will report to CEO and co-founder Anne Wojcicki.

Page's role as president begins on June 12. He was previously president of the Gilt Groupe, an online luxury shopping website, and chief operating and financial officer at PlayPhone. In his new position at 23andMe, Page will be in charge of the firm's product and engineering, marketing, finance, business development, laboratory operations, and legal/regulatory affairs functions. He will also identify long-term growth opportunities for 23andMe.

In appointing Page, Wojcicki reiterated the company's previously stated goal to garner one million customers by the end of the year. The company has lowered the price of its genomic testing services to $99 hoping to attract a more diverse customer base.

Wojcicki will focus on 23andMe's research organization and management activities. She and Page will work together on the company's business strategy. Page will remain a board member.


The Ludwig Institute for Cancer Research has appointed David Lane to be its new scientific director, effective June 1. He succeeds Andrew Simpson, who was scientific director for five years, from 2007 to 2012. Lane is chief scientist at Singapore's Agency for Science, Technology, and Research, and he will retain that post in addition to his new role at Ludwig.


Mollie Roth, former COO of the personalized medicine consultancy Diaceutics, has launched her own personalized medicine and life sciences consulting firm, PGx Consulting. Roth, an attorney by training, will provide a variety of services to the life sciences industry in the areas of strategic planning, operations, companion diagnostic contract negotiation, sales and marketing, legal, IT and network support, and SEO optimization.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.